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Pyrrolidine dithiocarbamate (PDTC) is an antiviral compound that was shown to inhibit the replication of
human rhinoviruses (HRVs), poliovirus, and influenza virus. To elucidate the mechanism of PDTC, the effects
on the individual steps of the infection cycle of HRV were investigated. PDTC did not interfere with receptor
binding or internalization by receptor mediated endocytosis of HRV2 particles into HeLa cells. But we
demonstrate that the processing of the viral polyprotein was prevented by PDTC treatment in HeLa cells
infected with HRV2. Furthermore, PDTC inhibited the replication of the viral RNA, even when added four
hours post infection. As PDTC is described as a metal ion binding agent, we investigated the effect of other
metal chelators on the multiplication of HRV2. We show that EDTA, -phenanthroline, and bathocuproine
disulfonic acid do not exhibit any antiviral properties. Surprisingly, these substances, coadministered with
PDTC, abolished the antiviral effect of PDTC, suggesting that metal ions play a pivotal role in the inhibition
of virus multiplication. These results suggest that PDTC inhibits the activity of the viral proteases in a metal
ion dependent way.
Human rhinoviruses (HRVs) are the most frequent cause of
the common cold and are implicated in more than 50% of
upper respiratory tract infections (45). Although not life
threatening, infection with HRV can prepare the ground for
more serious diseases, such as acute exacerbation of asthma
(20, 30) or otitis media (5). As there are more than 100 HRV
serotypes, vaccine development is unfeasible. Apart from
symptomatic medication no causative treatment for HRV in-
fections is currently available. Therefore, analysis of functions
of new antiviral substances is of great interest and might also
shed light on novel aspects of virus-cell interactions.
HRVs belong to the genus Picornaviridae. These viruses
have a single-stranded positive-sense RNA genome of approx-
imately 7,400 nucleotides. The viral RNA encodes four capsid
proteins (VP1 through VP4) and seven nonstructural proteins
that are involved in viral RNA replication and polyprotein
processing. The HRV serotypes can be classified into A and B
groups based on sequence alignments (36). Alternatively,
HRVs are divided into two groups according to their receptor
specificity (1, 49). Members of the major group HRVs bind to
the intercellular adhesion molecule 1 (ICAM-1) (15, 44),
whereas serotypes of the minor group use various members of
the low-density lipoprotein receptor family (18).
Upon receptor binding, the viral particle is internalized by
receptor-mediated endocytosis. After acidification of the late
endosome and subsequent uncoating, the RNA of minor group
HRVs is released into the cytoplasm (32). Then the viral RNA
is translated into a single large polyprotein from an internal
ribosome entry site (IRES), which is located in the 5 untrans-
lated region of the HRV genome. The polyprotein is processed
into the mature viral proteins through a sequence of cleavages
performed by two virus-encoded proteinases. The 2A protein-
ase (2Apro) cleaves between the C terminus of VP1 and its own
N terminus to separate the capsid protein region from the
nonstructural protein precursor (reviewed in reference 17).
Further processing is carried out by the 3C proteinase (3Cpro)
or its precursor 3CDpro. During infection the viral proteinases
also attack several cellular targets such as transcription and
translation factors or cytoskeletal proteins. The cleavage of
eukaryotic initiation factors 4GI (eIF4GI) and 4GII by 2Apro
leads to a shutoff of cap-dependent host cell protein synthesis
(10, 14).
Viral replication via a minus-strand intermediate and sub-
sequent synthesis of new positive-strand RNA is mediated by
the virus-encoded RNA-dependent RNA polymerase 3Dpol.
Finally, RNA and capsid proteins are assembled into mature
infectious viral particles, which are then released by cell de-
struction. During late stages of virus infection morphological
changes of cells can be observed, known as cytopathic effects.
Over the last two decades several steps in the life cycle of
HRV have been targets for antiviral therapy (39), such as viral
attachment, uncoating, polyprotein processing, and RNA po-
lymerization. So far, only limited success has been achieved by
the use of recombinant soluble receptor fragments to block
virus binding (26, 47). Promising clinical trials have been per-
formed with the capsid binding substance pleconaril (34) and
the 3Cpro inhibitor ruprintrivir (AG7088) (31).
Recently, we described pyrrolidine dithiocarbamate (PDTC)
as a potent inhibitor of HRV multiplication. PDTC is effective
against all tested HRV serotypes in several cell lines analyzed
without being toxic (11). In HeLa cells, the IC 50 against HRV
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14 is 60 M, toxic effects can be observed at concentrations
higher than 1 mM. Surprisingly, the antiviral activity of PDTC
is not restricted to members of the Picornaviridae such as HRV
or poliovirus, since PDTC was also shown to inhibit multipli-
cation of influenza virus, a member of the Orthomyxoviridae
(48; A. Grassauer, personal communication). Therefore, the
antiviral activity of this compound seems to involve more gen-
eral processes unidentified so far.
PDTC is a low-molecular-weight thiol compound that can
exert numerous effects in biological systems. It is a widely used
inhibitor of the activation of nuclear factor kappa B (NF-B)
(37, 38), although there are conflicting reports how this inhi-
bition is accomplished. On the one hand it has been attributed
to the antioxidative property of PDTC (2), on the other hand
to the inhibition of the ubiquitin ligase activity, which is a
prerequisite for NF-B activation (16). Furthermore, modula-
tion of the cellular availability of heavy metal ions is proposed
as another mechanism of the inhibition of NF-B activation by
PDTC (2, 38). PDTC binds various metal ions, leading to the
formation of lipophilic dithiocarbamate-metal complexes,
which transport metal ions such as zinc and copper from the
extracellular medium into the cell (9, 21, 43).
To gain insight into the mechanism by which PDTC blocks
the replication of HRV, we examined the effects on the various
steps of the viral life cycle in detail. Receptor binding and
internalization of HRV2 are not affected by PDTC. However,
we demonstrate that PDTC blocks processing of the viral
polyprotein. Addition of PDTC, even at 4 h postinfection,
results in a total inhibition of replication of both positive- and
negative-strand RNA.
As PDTC is a metal binding substance and several viral
processes were described to be influenced by various metals,
we investigated if the metal ion binding function of PDTC is
the mechanistic basis of the antiviral function. Interestingly,
the antiviral action of PDTC is abolished by the addition of
metal chelating agents, such as EDTA, -phenanthroline, or
bathocuproine disulfonic acid (BCS) and can be restored by
the concomitant addition of zinc and copper ions. These re-
sults suggest that metal ions play an important role for the
antiviral property of PDTC.
MATERIALS AND METHODS
Cells, media, and reagents. HeLa cells (strain Ohio; European Collection of
Cell Cultures, Salisbury, United Kingdom) were cultured in RPMI 1640 (Invitro-
gen) supplemented with 10% heat-inactivated fetal calf serum (Invitrogen), 2
mM L-glutamine (Dipro, Austria), 100 U/ml penicillin (Dipro), and 100 g/ml
streptomycin (Dipro).
Chemicals were obtained from Sigma. PDTC was purchased from Alexis
Biochemicals.
Virus preparation. HRV2 was obtained from the American Type Culture
Collection and routinely grown in suspension cultures of HeLa cells (strain Ohio;
Flow Laboratories, McLean; Virginia) as described previously (40). Virus titers
in 50% tissue culture infectious doses (TCID50)/ml were determined according
to Reed and Muench (33).
Infection of cells. HeLa cells seeded into 6-well tissue culture dishes were
infected at 70% confluence with HRV2 in RPMI medium supplemented with 2%
heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 g/ml streptomycin (infection medium). PDTC was added simultaneously
with HRV. Routinely, 125 M PDTC was used, which is nontoxic to HeLa cells
(11). Cells were incubated at 37°C and 5% CO2 in a humidified incubator. The
input virus was removed 2 h postinfection, and cells were washed once with an
acidic HEPES buffer (10 mM HEPES, 140 mM KCl; pH 5.3) and twice with
phosphate-buffered saline (PBS). For further incubation, infection medium and
PDTC were added when indicated.
Immunofluorescence. Immunofluorescence was essentially performed as de-
scribed elsewhere (3). Briefly, cells were grown on sterile coverslips in six-well
tissue culture dishes. Fixation was done with 4% paraformaldehyde–PBS at room
temperature (RT) for 10 min. Cells were permeabilized by incubation in 0.5%
Trition X-100 in PBS for 5 min. Blocking was done at 4°C using 1% goat
serum–PBS. As primary antibody the mouse monoclonal antibody 8F5 (1:200 in
PBS–1% bovine serum albumin) against the virus capsid protein VP2 (1:200) was
employed (29, 40). As secondary antibody, Alexa488-labeled goat anti-mouse
immunoglobulin G conjugates were used at a dilution of 1:800 (Molecular
Probes). Finally, slides were mounted with DAKO fluorescent mounting medium
and examined with a Leica TCS-NT confocal microscope using fluorescein iso-
thiocyanate settings.
Measurement of IRES-dependent translation. HeLa cells were infected with
HRV2 using the multiplicity of infection indicated in the figure legends. The
culture medium was removed 6 h postinfection, the cells were pretreated with
125 M PDTC or 125 M cycloheximide for 15 min and washed twice with PBS.
The cells were labeled in 1 ml per well of methionine- and cysteine-free RPMI
medium supplemented with 300 Ci of [35S]methionine/cysteine (radiochemical
purity by high-pressure liquid chromatography: 70% [35S]methionine, 25%
[35S]cysteine; Hartmann Analytic, Braunschweig, Germany) for 1 h. The labeling
was performed in the presence of PDTC or cycloheximide. Subsequently, pro-
teins were precipitated by trichloroacetic acid, and the incorporated radioactivity
was measured in a scintillation counter (Packard).
Pulse-labeling and immunoprecipitation. HeLa cells were infected with
HRV2. The infection medium was replaced by 1 ml per well of methionine- and
cysteine-free RPMI medium supplemented with 600 Ci of [35S]methionine/
cysteine (radiochemical purity by high-pressure liquid chromatography: 70%
[35S]methionine, 25% [35S]cysteine; Hartmann Analytic, Braunschweig, Ger-
many) at 6 h or 6.5 h postinfection During a labeling period of 1 h 125 M
PDTC, or 200 M zVAD.fmk (benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ke-
tone) were added. Protein extracts were prepared by addition of reducing sample
buffer (20% glycerol, 20% 2-mercaptoethanol, 8% sodium dodecyl sulfate [SDS],
0.04% bromophenol blue) and examined by SDS-polyacrylamide gel electro-
phoresis (PAGE). Alternatively, the cells were incubated in infection medium
supplemented with PDTC.
For immunoprecipitation the cells were washed twice with PBS, collected by
scraping in 1 ml of ice-cold PBS and centrifugation at 300  g for 4 min. Cell
pellets were frozen in liquid N2 and stored at 20°C. They were resuspended by
vortexing in 500 l of lysis buffer (1% [wt/vol] Triton X-100, 50 mM Tris-Cl, 300
mM NaCl, 5 mM EDTA, 0.02% Na-azide; pH 7.4) supplemented with 10 mM
iodoacetamide, 1 mM phenylmethylsulfonyl fluoride, and 2 g/ml leupeptin. The
samples were incubated on ice for 30 min and centrifuged at high speed in an
Eppendorf centrifuge at 4°C for 15 min. Meanwhile, 1 g of the monoclonal
antibody 8F5 specific for VP2 was coupled to 30 l 50% nProtein A-Sepharose
bead slurry (Amersham Bioscience) in 0.5 ml ice-cold PBS and 0.01% Triton
X-100. The beads were washed three times with lysis buffer; 500 l cell lysate and
the antibody-bound beads were combined and tumbled at 4°C for 2 h. The
protein-bead conjugates were washed twice with ice-cold PBS. Proteins were
resuspended in sample buffer, separated by SDS-PAGE and visualized by expo-
sure of the dried gel to BioMax MR x-ray film (Kodak).
Northern blotting. Total RNA was extracted from infected HeLa cells using
RNeasy mini kit (QIAGEN). 10 g of each sample were fractionated on a 1%
formaldehyde denaturing gel at 60 V, and the RNA quality was checked by
ethidium bromide staining to visualize the 18S and 28S rRNAs. RNA was
transferred to a Hybond N nylon membrane (Amersham) by wet blotting using
10x SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) buffer overnight
and UV-cross-linked (120 kJoule) in a Stratalinker (Stratagene). For synthesis of
strand-specific RNA probes, primer extension was performed in the presence of
[-32P]dCTP (purity 	98%; Hartmann Analytic, Braunschweig, Germany) using
the cDNA of HRV2 as a template (41).
The primers for the positive and negative strands were 5-TGGCCCTTGGA
ATATAGCTG-3 (located in the 2C coding region) and 5-CAGCTAGAGGG
CTTGAATGG-3 (located in the 3C coding region), respectively. The primer
extension reaction was set up as follows: 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM
dGTP, 2 M dCTP, 54 Ci of [-32P]dCTP, 25 pmol primer, 2.5 U Taq poly-
merase (Finnzymes, Espoo, Finnland), 5 ng of HRV2 template in reaction buffer
in a total volume of 50 l. Membranes were incubated in prehybridization
solution consisting of 25 ml 20x SSPE buffer (3 M NaCl, 0.25 M NaH2PO4, 0.02
M EDTA; pH 7.4), 50 ml 100% formamide, 10 ml blocking reagent (Roche), 1
ml 10% SDS, and H2O to 100 ml at 42°C for 2 h. Labeled RNA probes were
denatured at 95°C for 5 min and added to the prehybridizing solution. Mem-
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branes were incubated at 42°C overnight. After stringency washes (2x SSC buffer,
0.1% SDS), membranes were exposed to BioMax MR X-ray film (Kodak).
RESULTS
PDTC does not alter the infectivity of HRV particles. Over
the past two decades, antirhinoviral agents inhibiting viral at-
tachment and/or uncoating were developed, e.g., WIN com-
pounds and pleconaril (4). To find out whether PDTC interacts
with the viral capsid, HRV2 particles were incubated with
PDTC at room temperature for 1 h. Afterwards, HeLa cells
were incubated with PDTC-treated or untreated virus at 4°C
for 1 h. Under these conditions, receptor binding but no fur-
ther internalization can take place. Unbound virus was re-
moved by extensive washing and infection was continued by
cultivating cells in infection medium without PDTC at 37°C.
The virus titer of the supernatant was determined by titration
using TCID50 assays 24 h postinfection.
Infection of HeLa cells with PDTC-treated virus resulted in
a titer of 1.8  106. A similar titer was obtained in control
infections with untreated virus (Fig. 1). In contrast, continuous
presence of PDTC during infection led to a significant reduc-
tion of the virus titer of three orders of magnitude (Fig. 1) (11).
Thus, PDTC inhibits the multiplication of HRV2 when present
during the infection, but it does not directly interact with or
inactivate HRV2 particles.
Receptor binding and internalization of HRV2 is not af-
fected by PDTC. HRV enters the cell by receptor-mediated
endocytosis. Minor group serotypes like HRV2 bind to mem-
bers of the low-density lipoprotein receptor family (18). To
investigate the effect of PDTC on receptor binding and inter-
nalization of HRV2, the localization of the virus particles dur-
ing infection was monitored by immunofluorescence staining
of the virus capsid protein VP2.
An infection period of 20 min resulted in a uniform distri-
bution of the HRV2 particles in the cytoplasm of the HeLa
cells (Fig. 2a); 60 min postinfection the virus accumulated in
the perinuclear region, which is the characteristic localization
of late endosomes. HeLa cells infected with HRV undergo
morphological changes, like cell rounding and detachment
from the substrate, described as cytopathic effect. As a com-
plete life cycle of HRV2 in HeLa cells lasts approximately 10 h,
the cytopathic effect became visible 8 h postinfection, and the
cytoplasm of the infected cells were filled with progeny viral
particles (Fig. 2c).
In the presence of PDTC the amount and distribution of
HRV2 particles was similar to that of nontreated cells at 20
and 60 min postinfection (Fig. 2). Thus, the initial steps of virus
infection such as receptor binding and internalization are not
affected by PDTC.
However, treatment with PDTC completely inhibited the
multiplication of viral particles at 8 h postinfection, and later
on a loss of intracellular viral particles was observed (Fig. 2 and
data not shown). In addition, PDTC prevented the formation
of a visible cytopathic effect.
PDTC has no major effect on IRES-dependent translation.
During rhinoviral infection the cellular cap-dependent trans-
lation is inhibited by the host cell shut-off. This is achieved by
cleavage of the cellular translation factors eIF4GI and eIF4GII
by the viral protease 2Apro (10, 14). However, translation of
the HRV RNA genome is unaffected, as it is initiated at an
internal ribosomal entry site (IRES) via a cap-independent
mechanism. In the presence of PDTC no significant synthesis
of viral proteins can be detected (see Fig. 2A in reference 11).
Among other reasons, this can be due to decreased viral trans-
lation or impaired polyprotein processing.
To investigate the effect of PDTC on IRES-dependent trans-
lation the level of protein synthesis was determined after onset
of host cell shut-off in cells infected with HRV2 by incorpora-
tion of [35S]methionine/cysteine for 1 h followed by trichloro-
acetic acid precipitation of the proteins and scintillation count-
ing. During the labeling period cells were treated with PDTC
or cycloheximide, a strong inhibitor of both cap- and IRES-
dependent translation. PDTC slightly reduced the level of
IRES-dependent translation (about 80% compared to un-
treated cells), whereas cycloheximide significantly decreased
FIG. 1. PDTC does not inactivate or interact with the virus capsid.
HRV2 virus was preincubated with 125 M PDTC for 1 h. HeLa cells
were infected with pretreated or untreated HRV2 (multiplicity of
infection, 20) for 1 h at 4°C. Unbound virus was washed away and cells
were incubated in infection medium supplemented with 125 M
PDTC where indicated at 37°C. Virus titers of the supernatants were
determined by TCID50 assay after 24 h. FIG. 2. PDTC does not interfere with internalization of HRV2.HeLa cells grown on coverslips were infected with HRV2 (multiplicity
of infection, 50) in the absence or presence of 125 M PDTC. Cells
were fixed using 4% paraformaldehyde 20 min, 60 min, and 8 h postin-
fection The virus capsid protein VP2 was localized by the monoclonal
antibody 8F5 and visualized by immunofluorescence.
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the level of translation to about 20% (Fig. 3). This weak effect
of PDTC on IRES-dependent translation is unlikely to be
responsible for the absence of newly synthesized capsid pro-
teins.
PDTC interferes with polyprotein processing of HRV2.
Upon infection the HRV genome is translated into a large
polyprotein precursor, which is subsequently cleaved by a se-
quence of proteolytic cleavages. To investigate the effect of
PDTC on the processing of the viral polyprotein we analyzed
the pattern of virus protein precursors in the presence and
absence of PDTC by pulse-labeling. As a positive control we
employed the methylated form of the caspase inhibitor
zVAD.fmk, which was recently described to inhibit HRV 2Apro
and possibly 3Cpro (8).
HeLa cells were infected with HRV2. After host cell shutoff
newly synthesized proteins were labeled while administering
PDTC or zVAD.fmk. Subsequently, the protein pattern was
analyzed by SDS-PAGE and autoradiography.
Infection with HRV2 resulted in complete inhibition of host
cell protein synthesis at 6.5 h postinfection, but the viral pro-
teins were clearly expressed (Fig. 4A). Addition of PDTC led
to an accumulation of the uncleaved protein precursors P1, P2,
and P3. A reduction of processed proteins, as VP0, 2C, and
VP3 was observed. Incubation with zVAD.fmk caused a sim-
ilar pattern as obtained in the presence of PDTC. This strongly
suggests that PDTC interferes with polyprotein processing by
interfering with protease activity.
The effects on polyprotein processing were investigated in
more detail by analyzing the effects on P1 processing. To this
end, a pulse-chase labeling experiment followed by immuno-
precipitation with a VP2 specific antibody was performed.
Newly synthesized proteins of cells infected with HRV2 were
labeled for 60 min starting at 6 h postinfection after 30 min of
incubation with 125 M PDTC. Then the cells were incubated
in infection medium supplemented with PDTC and cell lysates
were prepared from 7 to 9 h postinfection. VP2 and VP2-
containing intermediate precursor proteins were immunopre-
cipitated with the monoclonal antibody 8F5 (40), and analyzed
by SDS-PAGE and autoradiography. To clearly identify VP2,
bands were compared to radiolabeled HRV 2 virus separated
simultaneously (lane *HRV2) (28).
In untreated cells the processing of the P1 precursor protein
was clearly visible as a reduction of the amount of the corre-
sponding polyprotein band. At the same time a smaller band
comprising VP2 appeared (Fig. 4B). In the presence of PDTC
the processing of the P1 protein was blocked and no cleavage
products could be detected.
Furthermore, we were interested whether the inhibitory ef-
fect of PDTC on the processing of the polyprotein does de-
pend on de novo protein synthesis. To this end, proteins of
infected cells were labeled for 15 min starting at 6 h 45 min
postinfection. Afterwards, the cells were treated with PDTC
and/or cycloheximide for 2 h. Again, virus proteins were ana-
lyzed by SDS-PAGE and autoradiography.
In untreated cells the large precursor molecules were pro-
cessed into the various viral proteins (Fig. 4C). Cycloheximide
did not interfere with the viral polyprotein processing. How-
ever, P1 protein processing was impaired in the presence of
PDTC, resulting in P1 accumulation. When PDTC and cyclo-
heximide were coadministered, the pattern of the virus pro-
teins was similar to that of PDTC-treated cells alone. This
indicates that the inhibitory effect of PDTC on polyprotein
processing does not depend on de novo protein synthesis.
PDTC decreases positive- and negative-strand RNA synthe-
sis of HRV2. To determine whether PDTC affects the synthesis
of the positive or negative strand RNA of HRV, the amount of
both RNA species was quantified by Northern blot analysis
with strand-specific probes.
In untreated cells an increase in both positive- and negative-
strand RNA levels was detected starting 4 h postinfection,
which resulted in a peak RNA level at 8 h postinfection (Fig.
5). At 13 h postinfection the level of viral RNA decreased
again due to the cytopathic effect. In contrast, addition of
PDTC at the onset of viral RNA synthesis 4 h postinfection
gave rise to an immediate and strong inhibition of both positive
and negative strand RNA replication (Fig. 5). Viral RNA syn-
thesis is also reduced to the same extent when PDTC is ad-
ministered at the time of infection (data not shown).
Thus, PDTC strongly inhibits viral RNA synthesis of both
positive and negative strands. A repression of replication of
virus RNA by PDTC was also observed for the major group
virus HRV14 (data not shown).
Antiviral effect of PDTC is abolished by metal ion chelating
agents. Previously, Erl et al. showed that PDTC can increase
the intracellular concentration of various metal ions (9). As the
activity of several viral enzymes was described to be influenced
by metal ions, we employed metal-chelating substances. In this
context it has to be noted that several biological effects of
PDTC, such as inhibition of the activation of NF-B or induc-
tion of apoptosis in endothelial cells, are abolished in the
presence of metal ion chelators (21, 22).
To investigate whether the antiviral effect of PDTC was
dependent on its ability to bind metal ions, other metal ion
chelators such as -phenanthroline, BCS, or free-base EDTA
were added during virus infection. The amount of progeny
virus in the supernatant was determined by TCID50 assays 24 h
FIG. 3. PDTC has no major effect on IRES dependent translation.
At 6 h p.i. the level of IRES-dependent protein synthesis in HeLa cells,
infected with HRV2 (multiplicity of infection, 100), was determined by
metabolic labeling for 1 h; 125 M PDTC or 125 M cycloheximide
(CHX) was added 15 min before the labeling and present during the
period of the pulse. The amount of incorporated [35S]methionine/
cysteine was determined by protein precipitation and measurement by
scintillation counting. Error bars indicate the standard deviation from
experiments carried out in triplicate.
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postinfection. The multiplication of HRV2 was not affected by
these metal chelators at the concentrations used, which is in
agreement with published data, where 1,000-fold higher con-
centrations of EDTA were shown to interfere with receptor
binding (data not shown) (25). However, coadministration of
metal chelators and PDTC abolished the antiviral effect of
PDTC. As shown in Fig. 6 the virus titer of HRV2 was reduced
by PDTC alone about three orders of magnitude compared to
controls. When BCS was added simultaneously the antiviral
effect was abolished in a dose-dependent manner, leading to
normal virus replication as in untreated cells at 1,000 M BCS
(Fig. 6A). Similar effects were observed after coadministration
of EDTA or -phenanthroline (Fig. 6B and C). EDTA was
much more potent in terms of inhibiting the effect of PDTC, as
10 M EDTA was already sufficient compared to 62 M
-phenanthroline. Interestingly, both the cell-permeable agent
-phenanthroline and the non-cell-permeable substances
EDTA and BCS were effective.
Copper and zinc ions are involved in the antiviral effect of
PDTC. Several divalent metal ions, including copper and zinc,
have been shown to contribute to some of the biological effects
of PDTC, such as the inhibition of NF-B and induction of cell
apoptosis (6, 9, 21, 22). We analyzed whether zinc, iron, or
copper ions could restore the antiviral effect of PDTC when it
is suppressed by EDTA (as shown in Fig. 6). Addition of at
least 2.5 M Zn2 ions or 25 M Cu2 ions reestablished the
antiviral activity of PDTC in the presence of EDTA (Fig. 7A
and C). Iron ions failed to show an effect (Fig. 7B). None of
these metal ions alone showed any antiviral activity in the
concentrations used (Fig. 7) and no cytotoxicity was observed
(data not shown). These results suggest that Zn2 or Cu2 ions
are an important factor for the antiviral effect of PDTC.
DISCUSSION
Currently, there is no cure available for the common cold
apart from symptomatic treatment. PDTC was shown to be a
potent inhibitor of the multiplication of HRV and poliovirus,
both members of the Picornaviridae (11). Furthermore, PDTC
turned out to prevent the multiplication of influenza virus,
belonging to the Orthomyxoviridae (48). This indicates that the
FIG. 4. PDTC interferes with the polyprotein processing. (A) Viral
proteins in HeLa cells, infected with HRV2 (multiplicity of infection
100), were labeled by incorporation of [35S]methionine/cysteine for 1 h
starting 6 h 30 min p.i. in the presence of 125 M PDTC or 200 M
zVAD.fmk. Cell lysates were prepared and analyzed by SDS-PAGE
and autoradiography. (B) HeLa cells, infected with HRV2 (multiplicity
of infection, 50), were preincubated with PDTC for 30 min and sub-
sequently incubated in medium supplemented with [35S]methionine/
cysteine and 125 M PDTC to label viral proteins for 60 min starting
6 h p.i. Then the cells were transferred to infection medium containing
125 M PDTC. Cell lysates were prepared every hour. VP2 or VP2
comprising precursor proteins were isolated by immunoprecipitation
employing the specific antibody 8F5 and analyzed by SDS-PAGE and
autoradiography. Radiolabeled HRV2 was separated in parallel to
identify viral capsid proteins (*HRV2). Mock designates immunopre-
cipitation from uninfected but labeled cells. (C) Viral proteins were
labeled in virus-infected HeLa cells, infected with HRV2 (multiplicity
of infection 50), for 15 min starting 6 h 45 min p.i. Subsequently the
cells were treated with 125 M PDTC or 125 M cycloheximide for
2 h. Cell lysates were prepared and proteins were analyzed by SDS-
PAGE and autoradiography.
FIG. 5. PDTC decreases the replication of positive and negative
strand RNA of HRV2. HeLa cells were infected with HRV2 (multi-
plicity of infection, 20). At the start of viral RNA replication at 4 h p.i.
PDTC was added where indicated (). Total RNA was isolated 1, 2, 4,
6, 8, and 13 h p.i. The level of positive- and negative-strand HRV2
RNA was quantitated by Northern blot analysis using strand-specific
probes generated by primer extension in the presence of [-32P]dCTP
and visualized by autoradiography. Analysis of the 28S rRNA ensured
an equal loading.
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antiviral effect of PDTC is not restricted to one distinct virus
family, and thus its mode of action might rely on more general
mechanisms. The precise molecular basis of the inhibitory
function has not yet been determined.
To elucidate the action of PDTC on HRV multiplication in
more detail, we investigated the effect of PDTC on single steps
of the infection cycle of HRV2. We demonstrated that PDTC
did not affect the early steps of the viral infection cycle, such as
receptor binding, virus entry, and internalization. Thus, PDTC
does not interact with the capsid of HRV2, as preexposure of
the virus to PDTC did not alter the infectivity of HRV particles
(Fig. 1). Moreover, PDTC does not interfere with virus entry,
since binding to the cellular receptor and receptor-mediated
endocytosis were unaffected by PDTC (Fig. 2). Although
PDTC slightly decreased IRES-dependent translation, this ef-
fect is too weak to be exclusively responsible for the antiviral
property of PDTC (Fig. 3).
However, our data indicate that PDTC impedes the process-
ing of the HRV polyprotein (Fig. 4). As PDTC treatment
abolished the appearance of processed VP2 an inhibition of
the viral proteases 2Apro and/or 3Cpro is proposed (Fig. 4B). As
a consequence of the impaired polyprotein processing, the
repressed replication of both positive- and negative-strand
RNA in the presence of PDTC might be due to alterations in
the processing and production of the nonstructural proteins
(Fig. 5).
In account of their important roles in the processing of the
FIG. 6. Antiviral effect of PDTC is abolished by metal chelators.
HeLa cells, infected with HRV2 (multiplicity of infection 20), were
treated with the metal chelators BCS (A), EDTA (B), or -phenan-
throline (C). 125 M PDTC were added simultaneously. The virus
titers in the supernatant of the infected cells were determined by
TCID50 assay 24 h p.i.
FIG. 7. Zinc and copper ions are involved in the antiviral effect of
PDTC. HeLa cells, infected with HRV2 (multiplicity of infection, 20),
were treated with 125 M PDTC and 2.5 M EDTA (dark bars).
Simultaneously, Zn2 (A), Fe2 (B), or Cu2 (C) ions were added.
The virus titers in the supernatant of the infected cells were deter-
mined by TCID50 assay at 24 h p.i. Light bars represent cells treated
with the respective ions but without PDTC and without EDTA.
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viral polyprotein, blocking of the viral proteases 2Apro and
3Cpro is regarded as a promising approach to antiviral therapy
(27, 35, 45). Recently, we demonstrated that inhibition of the
viral protease 2Apro with the methylated form of the caspase
inhibitor zVAD.fmk resulted in a significant decrease of mul-
tiplication of HRV (8). The most promising HRV protease
inhibitor currently available is the 3Cpro inhibitor ruprintrivir,
which shows potent activity for a broad spectrum of rhinovirus
serotypes (31).
Previously, we have described that PDTC does not inhibit
the activity of the HRV2 2Apro in vitro, as was shown by using
purified protease and cleavage of synthetic peptide substrates
(11). Furthermore, PDTC failed to inhibit 2Apro-mediated
cleavage of eIF4GI and cytokeratin 8 in cell extracts. No inhi-
bition of eIF4GI cleavage was found in rabbit reticulocyte
lysates during translation of mRNAs encoding HRV2 2Apro
(data not shown). Nevertheless, in a cellular context PDTC
might change the cytoplasmic environment, thereby interfering
with 2Apro and/or 3Cpro function.
Dithiocarbamates can chelate various metal ions, leading to
the formation of lipophilic dithiocarbamate-metal complexes
(43). Several studies have reported that dithiocarbamates can
promote cell entry of metals, e.g., diethyldithiocarbamate and
PDTC increased the intracellular copper levels in thymocytes
(9). Kim et al. demonstrated that PDTC gave rise to uptake of
zinc ions (22). These data suggest that PDTC might alter the
tightly regulated balance of ions in cells, resulting in alterations
of enzyme functions. In some reports it was described that
various biological effects of PDTC can be prevented by the
addition of metal chelators (21, 22). In this manuscript we
demonstrate that the antiviral effect of PDTC was neutralized
by addition of free-base EDTA, -phenanthroline, or BCS.
Thus, it seems that the availability of ions is crucial for the
antiviral action of PDTC (Fig. 6).
Among metal ions, zinc has been known to interfere with
HRV replication for many years. As a mechanism, the inhibi-
tion of the posttranslational cleavage of the precursor protein
was suggested (23, 24). Cordingley et al. described that 3Cpro is
inhibited by zinc ions in an in vitro protease assay (7). In
contrast, there is no effect of zinc ions on the 2Apro self-
processing or cleavage of eIF4GI determined by in vitro trans-
lation of HRV2 mRNA in rabbit reticulocyte lysate (13).
Comparison of the antiviral activities of various zinc salts
showed that the therapeutic index is very low (12). There are
conflicting results on the effectiveness of zinc gluconate or zinc
acetate in the treatment of the common cold in clinical trials
(42, 46).
However, it cannot be excluded that PDTC has an impact on
viral enzymes other than proteases. Zinc ions are described to
inhibit the activity of the 3Dpol of HRV16 in vitro (19). Thus,
by increasing the intracellular zinc ion concentration PDTC
might directly inhibit polymerase function and replication.
In our report, we propose a model for the antiviral effect of
PDTC on HRV. We demonstrated that PDTC interferes with
polyprotein processing. Moreover, the level of virus RNA was
decreased in PDTC-treated cells. However, our results exclude
an action of PDTC on the early steps of virus infection, such as
receptor binding or internalization. Since the antiviral effect of
PDTC is abolished in the presence of several metal ion-che-
lating compounds, the antiviral activity of PDTC seems to
depend on the availability of metal ions. Specifically, zinc or
copper ions seem to play a crucial role, as they restore the
antiviral property of PDTC in the presence of EDTA.
However, to date it is unclear if PDTC works as a carrier for
the ion or if binding of an ion is necessary to allow PDTC to
enter the cell. Elucidation of the antiviral mechanism of PDTC
will be the subject of further research and will provide more
information about the environmental requirements for the rhi-
novirus life cycle.
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